Why REGENXBIO Inc.’s (RGNX) Stock Is Up 6.17%
As of Monday, July 27, REGENXBIO Inc.’s RGNX share price has surged by 6.17%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why REGENXBIO Inc.’s (RGNX) Stock Is Down 5.01%
As of Friday, July 24, REGENXBIO Inc.’s RGNX share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why REGENXBIO Inc.’s (RGNX) Stock Is Up 5.16%
As of Monday, July 20, REGENXBIO Inc.’s RGNX share price has surged by 5.16%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why REGENXBIO Inc.’s (RGNX) Stock Is Down 20.36%
As of Friday, July 17, REGENXBIO Inc.’s RGNX share price has dipped by 20.36%, which has investors questioning if this is right time to buy.Jenna Brashear
Why REGENXBIO Inc.’s (RGNX) Stock Is Down 12.32%
As of Friday, July 17, REGENXBIO Inc.’s RGNX share price has dipped by 12.32%, which has investors questioning if this is right time to buy.Tudor Pop
Financial Summary
| Share Statistics | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $597.9 | $252.6 | 40% |
|
| Shares Out (Mil) | 52.4 | 52.3 | 49% |
|
| Institutional Ownership | 89.4% | 92.1% | 57% |
|
| Float (Mil) | 53.0 | 40.2 | 49% |
|
| Beta | 1.12 | 0.95 | 66% |
|
| Avg Daily Volume (000s) | 1,385 | 455 | 76% |
|
| Price Change (52-week) |
10.7% | 52.9% | 54% |
|
| Growth | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.0% | 13.6% | 23% |
|
| Net Income (5yr) | (11.7%) | (9.9%) | 27% |
|
| EPS (5yr) | (4.7%) | 16.0% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.6%) | (15.6%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 7 | |
| Current EPS | ($0.108) | ($2.791) | ($2.543) | |
| Month Ago EPS | $0.119 | ($2.824) | ($2.575) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.100 | ($1.999) | ($2.196) | |
| Year/Year Chg | (93.7%) | (25.8%) | (26.3%) | |
| Financials | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $88 | $38 | 25% |
|
| Net Income (TTM) (Mil) | ($290) | ($43) | 5% |
|
| EPS (TTM) | ($5.594) | ($1.600) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($234) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($115) | $5 | 13% |
|
| Long-Term Debt (Q1) (Mil) | $226 | $5 | 51% |
|
| Enterprise Value (Q1) (Mil) | $421 | $180 | 33% |
|
| Valuation | RGNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 23.63 | 2.56 | 96% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (196.6%) | 63.8% | 1% |
|
| Net Margin | (330.2%) | (67.3%) | 3% |
|
| ROA | (69.6%) | (49.8%) | 8% |
|
| ROE | (196.4%) | (55.5%) | 4% |
|
| Liabilities to Assets | 93.8% | 30.3% | 91% |
|
| F-Score | 1 | 3 | 1% |
|
REGENXBIO Inc. did not pass any screens on 7/31/2026.
